YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
European equities traded in the US as American depositary receipts were lower on Tuesday morning, de PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* Inventiva S.A press release [https://seekingalpha.com/pr/20665112-inventiva-reports-unaudited-2026-first-half-financial-results-and-provides-corporate-update] (IVA [https://seekingalpha.com/symbol/IVA]): there were no revenues recorded f…
By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company's opera…
Inventiva S.A. (NASDAQ:IVA) is one of the best strong buy penny stocks to invest in now. Inventiva S.A. (NASDAQ:IVA) announced on July 9 the completion of the final step of the transactions previously announced on June 2, 2026, through the…
Inventiva S.A. (NASDAQ:IVA) is one of the 10 best stocks under $10 offering more than 50% upside. As of the June 24 close, Inventiva S.A. (NASDAQ:IVA) had a strongly bullish consensus sentiment. The stock received Buy ratings from all 9 an…
Claret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASH Claret Capital Partners is providing growth funding of €43…
Claret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASH Claret Capital Partners is providing growth funding of €43…
Repaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warrants2 (corresponding to approximately 22.7…
Remboursement intégral des Prêts BEI existants1 d'un montant d'environ 62 millions d'euros et finalisation du rachat de tous les 2,266,023 BSA Tranche A BEI existants et de 700.000 BSA Tranche B BEI existants2 (correspondant à environ 22,7…
(RTTNews) - Inventiva S.A. (Euronext Paris and Nasdaq: IVA) a clinical-stage biopharmaceutical company focused on therapies for metabolic dysfunction-associated steatohepatitis (MASH), announced that trading of its ordinary shares on Euron…
Daix (France), New York City (New York, Etats-Unis), le 13 mai 2026 – Inventiva (Euronext Paris et NASDAQ: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique au stade clinique spécialisée dans le développement de thérapies p…
Daix (France), New York City (New York, United States), May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for t…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Inventiva’s updated analyst narrative now reflects a Fair Value move from €8.98 to about €10.00, a…
Chiffre d'affaires de 4,5 millions d'euros pour l’année 2025Trésorerie et équivalents de trésorerie à 99,3 millions d’euros et 131,6 millions d'euros en dépôts à court terme1 au 31 décembre 2025Réalisation d'une offre au public aux États-U…
Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering for gross proceeds of approximately…
Trésorerie et équivalents de trésorerie à 99,3 millions d’euros, et 131,6 millions d’euros en dépôts à court terme2 au 31 décembre 2025Chiffre d’affaires de 4,5 millions d’euros en 2025Réalisation d’une offre au public aux États-Unis pour…
Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€…
Last Friday, the three most widely followed benchmark indexes closed a mixed week. The S&P 500 and the Nasdaq Composite receded 0.1% and 1.9%, respectively, while the Dow Jones Industrial Average advanced 2.5%. Markets diverged last week m…
By Danilo Masoni MILAN, Jan 28 (Reuters) - A surge in Inventiva shares, up about 50% in the first few weeks of 2026, highlights investors' appetite for betting on the loss-making French biotech, which is on the verge of entering the fast-g…
Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molec…
Inventiva S.A. (NASDAQ:IVA) is one of the best multibagger penny stocks to buy right now. Inventiva (NASDAQ:IVA) commands a consensus Buy rating on Wall Street. The average price target for the stock is $17.86, implying 300.45% upside pote…
Daix (France), New York City (New York, Etats-Unis), le 28 novembre 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour l…
Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatme…
* Inventiva S.A. press release [https://seekingalpha.com/pr/20317481-inventiva-reports-2025-third-quarter-financial-information] (OTCPK:IVEVF [https://seekingalpha.com/symbol/IVEVF]): Revenues of €4.5 million for the first nine months of 2…
* Inventiva S.A (IVA [https://seekingalpha.com/symbol/IVA]): Revenues for the first nine months of 2025 amounted to €4.5 million, compared to none generated for the same period in 2024. * Cash and cash equivalents at €97.6 million, and €24…
Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the end of the first quarter of 20273, inc…
Trésorerie et équivalents de trésorerie à 97,6 millions d’euros, et 24,7 millions d’euros en dépôts à court terme2 au 30 septembre.Chiffre d’affaires de 4,5 millions d’euros sur les neuf premiers mois de 2025.Horizon de trésorerie prévue j…
Daix (France), New York City (New York, États-Unis), le 17 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour l…
Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies…
Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour l…
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies…
Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour l…
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies…
Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour l…
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies…
Daix (France), New York City (New York, États-Unis), 12 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le t…